UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **April 21, 2021**

TREVENA, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-36193**	**26-1469215**
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
(Address of principal executive offices and zip code)

(610) 354-8840
(Registrant's telephone number, including area code)

n/a
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.001 par value	TRVN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On April 21, 2021, Trevena, Inc. (the "Company") updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit 99.1.

The information set forth on this Item 7.01 and furnished hereto as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On April 21, 2021, the Company issued a press release announcing that TRV027, the Company's investigational, novel AT_1 receptor selective agonist, has been selected for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients being conducted and funded as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia). REMAP-CAP is financially supported by an array of governments and research organizations worldwide. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation Deck dated April 21, 2021
99.2	Press Release dated April 21, 2021
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TREVENA, INC.

Date: April 21, 2021

By: /s/ Barry Shin
Barry Shin
Senior Vice President &Chief Financial Officer

Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the "Company" or "we"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by terminology such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our potential drugs by physicians and patients; (v) the timing or likelihood of regulatory filings and approvals; and (vi) our cash needs.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of our clinical trials or any future trials of any of our investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including our assessment of the discussions with the FDA or other regulatory agencies about any and all of our programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to our intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of our therapeutic candidates; and other factors discussed in the Risk Factors set forth in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings we make with the SEC from time to time. In addition, the forward-looking statements included in this presentation represent our views only as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as may be required by law.

Trevena's Experienced Leadership Team

SENIOR MANAGEMENT		
Carrie L. Bourdow	President & Chief Executive Officer	CUBIST, MERCK
Scott Applebaum	SVP, Chief Legal & Regulatory Officer	Shire, vitae, Bristol Myers Squibb
Mark A. Demitrack, M.D.	SVP, Chief Medical Officer	NEURONETICS, Lilly, ROIVANT
Barry Shin	SVP, Chief Financial Officer	MIZUHO, GUGGENHEIM, PiperJaffray
Robert T. Yoder	SVP, Chief Commercial Officer	MERCK, OREXIGEN

BOARD OF DIRECTORS			
Leon O. Moulder, Jr. *Chairman*	TESARO, MGI	Marvin H. Johnson, Jr.	MERCK
Carrie L. Bourdow	Trevena	Julie H. McHugh	centocor, Johnson & Johnson, endo
Scott Braunstein, M.D.	MARINUS, AISLING CAPITAL, PACIRA	Jake R. Nunn	NEA
Michael R. Dougherty	Adolor, centocor	Anne M. Phillips, M.D.	novo nordisk
Maxine Gowen, Ph.D.	Trevena	Barbara Yanni	MERCK

Trevena: Innovative CNS Company

IV OLINVYK: Differentiated profile	NCE approved for the management of acute pain in adults Commercial launch in Q1 2021; targeting 100 formulary wins by year-end
Large market, targeted launch	45M+ US hospital patients; 9M procedures is initial core focus $1.5B+ market opportunity for core focus
Novel CNS pipeline	New mechanisms for acute migraine, opioid use disorder, epilepsy, pain NCEs targeting significant unmet needs
TRV027 for COVID-19	Novel MOA to treat COVID-19 acute lung injury / abnormal clotting REMAP-CAP trial – worldwide, adaptive, Phase 2 / 3 trial in up to 300 COVID-19 patients
Strong financial position	$109.4M cash and cash equivalents as of YE 2020 Funds operations through Q4 2022

OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

NCE = New Chemical Entity; MOA = Mechanism of Action; PoC = Proof-of-Concept

Multiple Expected Catalysts

	PRE-CLINICAL / PHASE 1 / PHASE 2 / PHASE 3 / NDA	EXPECTED CATALYSTS
OLINVYK™ New chemical entity (mu-opioid receptor)	Acute pain IV — APPROVED	**Q1 21:** Commercial launch
TRV027 Novel AT_1 receptor selective agonist	ARDS / abnormal clotting (COVID-19) IV — Collaborations with REMAP-CAP and ICL	Transition to REMAP-CAP trial
TRV250 G-protein selective agonist (delta receptor)	Acute migraine oral/subcutaneous	**1H 21:** IND-enabling activities (oral)
TRV734 G-protein selective agonist (mu-opioid receptor)	Opioid use disorder oral — Collaboration with National Institute on Drug Abuse	PoC study data (NIDA)
TRV045 Novel S1P receptor modulator	CNS disorders oral — Collaboration with National Institutes of Health	**1H 21:** IND filing

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

TRV250, TRV734, TRV027, and TRV045 are investigational products and are not approved by the FDA or any other regulatory agency.
ARDS = Acute Respiratory Distress Syndrome; IND = Investigational New Drug; PoC = Proof-of-Concept

OLINVYK: Differentiated Profile for Acute Pain

OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate

Data in complex patients
Elderly / obese, multiple comorbidities

New chemical entity
Distinct from IV morphine

Simplified, predictable dosing
No adjustment in renal impaired
No active metabolites

IV opioid efficacy
Hard- and soft-tissue surgeries

Well-characterized safety / tolerability
IV morphine data included in label

Rapid analgesia
1-3 min median onset of pain relief

Trevena

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

OLINVYK: Broad Indication for Acute Pain

Large acute market opportunity

US injectable analgesic hospital market unit volume[1]



45M patients receive IV opioids annually to treat acute pain[1]

- Unrivalled analgesic efficacy
- Top surgeries: Total knee arthroplasty, colectomy, hernia repair, spine fusion, C-section[2]

OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

NSAIDs = nonsteroidal anti-inflammatory drugs. 1) IMS MIDAS sales audit 2017; IV NSAIDs and Ofirmev®. 2) Definitive database, and National Vital Statistics report, CDC 2018.

OLINVYK: Well-Characterized Safety / Tolerability

Adverse drug reactions reported in ≥5% of OLINVYK-treated patients stratified by daily dose (Phase 3 pivotal trials pooled)[1]

	Placebo (N = 162)	OLINVYK ≤ 27 mg (N = 316)	Morphine (N = 158)
Patients with any TEAE (%)	73	86	96
Nausea	35	52	70
Vomiting	10	26	52
Headache	30	26	30
Dizziness	11	18	25
Constipation	9	14	14
Hypoxia	3	12	17
Pruritus	6	9	19
Sedation	5	7	13
Somnolence	4	6	10
Back pain	4	6	6
Hot flush	4	4	8
Pruritus gen.	1	2	10

Key cost-drivers associated with IV opioids:

- **Vomiting**
  - Can result in significant health risks and compromise recovery
- **Somnolence**
  - Significant patient safety concern, can lead to respiratory depression
- **O_2 saturation < 90%**
  - Independent predictor of early post-op respiratory complications

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

1) OLINVYK Prescribing Information. Not an adequate basis for comparison of rates between the OLINVYK treatment group and the morphine treatment group.

Real World Use: Complex Surgeries & Patients

Broad range of surgeries / medical procedures



Complex patients included

- 32% ≥ 65 years; 46% BMI ≥ 30
- Co-morbidities: diabetes, obstructive sleep apnea, COPD, chronic / cancer pain
- Concomitant medications: antiemetics, antibiotics

Multiple inpatient and hosp outpatient settings

- Hospital recovery
- Critical care
- Emergency department
- Ambulatory surgical centers

Low discontinuation for AEs / lack of efficacy

- 2% for adverse events
- 4% for lack of efficacy

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

Bergese SD et al. J Pain Research, 2019. Trial modeled real-world use: usual patient care with OLINVYK instead of standard IV opioid. See FDA draft guidance for Industry Distributing Scientific and Medical Publications on Unapproved New Uses.

OLINVYK: Ease of Dosing and Administration

3 vials allow for flexible and tailored IV dosing

- **Bolus Dosing:** 1 mg and 2 mg vials (single dose)
- **PCA Dosing:** 30 mg vial (single patient use)
- **OLINVYK 1 mg ≈ morphine 5 mg[1]**

27 mg cumulative daily dose limit

Do not administer single doses greater than 3 mg

No refrigeration / reconstitution

	1 mg / 1mL	2 mg / 2mL	30 mg / 30 mL
WAC:	$17.50	$25.75	$110.00

~$100 / day
(estimated avg cost across procedures)

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

1) For an initial dose. PCA = Patient-Controlled Analgesia

Customer Engagement Strategy

Targeted Account Launch

Initial focus: complex patients in 3 key surgical areas



ASCs = ambulatory surgical centers

Targeted Messaging and Resources

Key OLINVYK attributes focused on key customers

Health Care Practitioners (HCPs)

- OLINVYK: NCE, distinct from IV morphine
- Fast pain relief & no active metabolites
- Safety data in complex patients / surgeries

Targeted Accounts

- OLINVYK published safety data vs. IV morphine
- Published health economic / cost offset data*

Trevena

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

*Published by 1H 2021. Images: flaticon.com.

Robust Set of Peer-Reviewed Publications

Comprehensive overview of OLINVYK development program

OLINVYK nonclinical / Phase 1 / Phase 2 data

15 publications

OLINVYK Phase 3 trials & secondary analyses

9 publications

- 4 head-to-head studies vs. IV morphine
  - IV opioid efficacy
  - Well-characterized safety and tolerability
- Data in complex patients / surgery types
- Respiratory safety data in elderly / obese
- Respiratory safety profile measured by dosing interruptions
- Clinical utility vs. IV morphine - benefit-risk analysis
- Reduced risk of N / V - complete GI response analysis

Trevena

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

See www.trevena.com for full manuscripts and abstracts. These publications will be used in a manner consistent with FDAMA sections 114 and 401 and the FDA Guidances thereunder.

HECON Model Driven by Compelling Clinical Data

Publication of base and high-risk patient models expected 1H 2021

Representative Inputs:

AE rates

Ph3 trials



Vomiting
Somnolence / sedation
O_2 saturation <90%

Cost of AEs

Gov't sources / Publications

$8k nausea / vomiting[1]
$28k critical resp event[2]
+7 days hospital stay[2]

Drug cost

OLINVYK
Generic IV opioids

HECON model

Key Outputs:

>10x
Cost savings for hospitals[4]

Due to improved patient outcomes

Trevena

1) Oderda, GM, J Pain Palliative Care Pharm, 2019; data based on 5 surgical procedure categories including Cardiothoracic / vascular, General / Colorectal, Ob / Gyn, Orthopedic, and Urologic. 2) Overdyk FJ, PLoS One, 2016. More conservative inputs were used in the model. 4) Calculated based on total costs of Tx and total costs of care. Image: flaticon.com.

Hospital Formulary Review Process



Submits request for drug review

Conducts formal assessment of the drug

Reviews assessment / votes to revise formulary

Updates formulary, protocols / order sets

YE 2021 target: 100 formulary wins

Trevena

Differentiated Profile For Use in Hosp Outpatient & ASCs

Separate reimbursement may provide lower access hurdle

Physician trial in outpatient can accelerate inpatient uptake

Improves patient throughput / time to discharge

Streamlines dosing for short-term setting of care

Addresses shift to complex patients

ASC = ambulatory surgery center. PK = pharmacokinetic. Images: www.flaticon.com

We Continue to Learn from and Adapt to COVID-19 Challenges

Transitioned into commercial organization with minimal business interruption

- No delays in regulatory timelines; approval and DEA scheduling in 2H 2020
- Commercial supply of all 3 presentations made available to customers

What we learned from our customers

- Procedure volumes may be slow to recover; backlog of elective surgeries building[1]
- IV drug shortages, increase in patient acuity continue to pressure healthcare systems

Considerations for a successful field launch in 2021

- COVID-19 will continue impacting our customers; OLINVYK's value proposition remains relevant
- We will be making informed resource deployment decisions throughout first year of launch

1) Kaufman Hall 2020 State of Healthcare Performance Improvement Report: The Impact of COVID-19, October 2020.

OLINVYK: Significant Opportunity in Acute Pain



Initial core focus (9M)

- Hospitals / ambulatory surgical centers
- "CORES" patient focus: comorbid, obese, renal, elderly, sleep apnea

~15M days of therapy (initial focus) = **$1.5B+ market opportunity***

Expanded areas of focus (28M)

- Leverage respiratory and GI safety vs. IV morphine to expand surgical procedures
- Cognitive function & additional HECON

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

*Source: Definitive Healthcare; American Hospital Association. *Assumes ~$100/day price for oliceridine 2032 composition of matter patent expiration does not include potential patent extensions.*

TRV027

NCE targeting the AT_1 receptor in COVID-19

Trevena

Multi-Organ Damage From Coronavirus

Elimination of ACE2 protein leads to critical hormonal imbalances

Coronavirus binds to and eliminates ACE2[1]



- Leads to accumulation of angiotensin II:
  - Acute lung injury and abnormal blood clots
  - Can lead to ARDS / pulmonary embolism / stroke
- 66% - 94% mortality rate for COVID-19 related ARDS[2*]
- ~1/3 of hospitalized COVID-19 patients develop clotting complications[3]

ARDS = Acute Respiratory Distress Syndrome. 1) Kuba K et al., Nat Med, 2005. 2) Gibson PG et al, Med J Aust, 2020. *In patients requiring ventilation. 3) Klok FA et al, Thromb Res, 2020.

TRV027: New MOA for COVID-19

Mechanism targeted to improve lung function and prevent abnormal clotting



TRV027 is the only selective AT_1 receptor agonist
Safety / tolerability established in ~700 patients

TRV027 COVID-19 Study - REMAP-CAP

REMAP-CAP is a global clinical trial network led by experts in pandemic response

- Multi-site, adaptive, Phase 2 / 3 trial in COVID-19 patients
- 200 - 300 COVID-19 patients
  - Hospitalized patients, including those admitted to ICU
  - ≥18 years old
- TRV027 being administered in conjunction w/ACE inhibitor

Primary outcome:

In-hospital mortality + organ failure support in ICU after 21 days following randomization

Additional clinical outcomes: ICU and hospital length of stay, ventilator-free days, organ failure-free days

REMAP-CAP
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia

Trevena

* Primary endpoint: D-dimer levels. https://clinicaltrials.gov/ct2/show/record/NCT04419610.

Multiple Expected Catalysts

	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	NDA	EXPECTED CATALYSTS
OLINVYK™ New chemical entity (mu-opioid receptor)	Acute pain IV				APPROVED	Q1 21: Commercial launch
TRV027 Novel AT_1 receptor selective agonist	ARDS / abnormal clotting (COVID-19) IV		Collaborations with REMAP-CAP and ICL			Transition to REMAP-CAP trial
TRV250 G-protein selective agonist (delta receptor)	Acute migraine oral/subcutaneous					1H 21: IND-enabling activities (oral)
TRV734 G-protein selective agonist (mu-opioid receptor)	Opioid use disorder oral		Collaboration with National Institute on Drug Abuse			PoC study data (NIDA)
TRV045 Novel S1P receptor modulator	CNS disorders oral		Collaboration with National Institutes of Health			1H 21: IND filing

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

TRV250, TRV734, TRV027, and TRV045 are investigational products and are not approved by the FDA or any other regulatory agency.
ARDS = Acute Respiratory Distress Syndrome; IND = Investigational New Drug; PoC = Proof-of-Concept

TRV250: New MOA for Acute Treatment of Migraine

Delta receptor: Untapped potential in CNS space
Migraine represents a large market opportunity; total migraine drug market = ~$3.5B

Delta receptors have unique distribution throughout the brain

Play important role in regulation of pain, mood, and anxiety

Every year in the US[1]:

650M migraines treated each year

1.2M ER visits due to migraines

- **20-30%** of migraine sufferers do not respond to / cannot tolerate the market-leading triptan drug class
- Approx. **50%** of migraineurs also suffer from anxiety[2]

Trevena

1) Data from Decision Resources, Pharmacor migraine market landscape and forecast 2018. 2) Moven et al., J Neurol Neurosurg Psychiatry, 2016.
Icons made by Freepik from www.flaticon.com

TRV250: Well-Tolerated in Ph1 Healthy Volunteer PK Study

Subcutaneous doses up to 30 mg studied; no SAEs observed

Single dose pharmacokinetics of TRV250 given by SC injection



- Well tolerated, with no SAEs across broad range of doses
- Predictable PK: dose-proportional between 0.1 mg to 30 mg SC
- Half-life consistent across all doses
- No EEG findings observed in any subject

IND-enabling activities initiated for new oral dose form

Trevena

SC = subcutaneous. Fossler MJ et al., CNS Drugs, Aug 2020;34(8):853-865.

TRV734: Maintenance Therapy for Opioid Use Disorder

Selective agonism at μ receptor: Potential for improved tolerability

Ongoing collaboration with National Institute on Drug Abuse (NIDA)

- Nonclinical evidence of improved tolerability with TRV734
- NIDA study demonstrated reduced drug-seeking behavior in animal model of relapse[2]
- Current therapies not well tolerated, can hinder patient adherence

NIDA-funded proof-of-concept patient study initiated

1) Center for Behavioral Health Statistics and Quality. 2) NIDA data on file.

TRV045: Selective S1PR With No Lymphopenia

Uniquely selective for S1P-subtype 1 receptor

$S1P_1$ receptors are expressed broadly in the CNS

Potential role in the treatment of:

Epilepsy

- Neuroprotective effects[1]
- Modulates permeability of BBB, anti-inflammatory effects[2]

Chronic neuropathic pain

- Inhibits pain sensation[3]
- Inhibits excitatory neuronal signaling[4]

Avoids known safety issues associated with S1P receptor subtypes 2, 3, 4, 5:

Pulmonary, cardiac, and cancer-related effects[5]

1) Gol et al., European Journal of Pharmaceutical Sciences, 2017. 2) Leo et al., CNS & Neurological Disorders - Drug Targets, 2017. 3) Sim-Selley et al., Journal of Pharmacology & Experimental Therapeutics, 2018. 4) Sim-Selley et al, Journal of Neurochemistry, 2008. 5) Lymphopenia, bradycardia, vascular leakage, macular edema. BBB = blood-brain barrier. Images: flaticon.com.

TRV045: Engages S1PR Without Lymphopenia in CIPN Model

S1P receptor activation conventionally associated with lymphopenia / immunosuppression

- In animals, TRV045 reversed paclitaxel-induced hyperalgesia without immune-suppressing activity
  - Fingolimod reduced lymphocytes by 78%
  - TRV045 had no effect on lymphocytes
- Non-opioid MOA with broad potential for CNS indications
  - Chronic pain, CIPN, diabetic neuropathy
  - Epilepsy, acute / chronic pain evaluations underway



Trevena

*CIPN mouse model: Paclitaxel 6 mg/kg, i.p. on Days 1, 3, 5, 7. Hyperalgesia measured as % non-response to 0.4 g Von Frey filament vs. baseline, tested 30' after dosing on Day 13. Lymphocytes measured after 3 days of dosing. Data are mean ± s.e.m. n=5-7 mice/group. *p<0.05 or **p<0.01 vs. control*

Trevena: Innovative CNS Company

IV OLINVYK: Differentiated profile	NCE approved for the management of acute pain in adults Commercial launch in Q1 2021; targeting 100 formulary wins by year-end
Large market, targeted launch	45M+ US hospital patients; 9M procedures is initial core focus $1.5B+ market opportunity for core focus
Novel CNS pipeline	New mechanisms for acute migraine, opioid use disorder, epilepsy, pain NCEs targeting significant unmet needs
TRV027 for COVID-19	Novel MOA to treat COVID-19 acute lung injury / abnormal clotting REMAP-CAP trial – worldwide, adaptive, Phase 2 / 3 trial in up to 300 COVID-19 patients
Strong financial position	$109.4M cash and cash equivalents as of YE 2020 Funds operations through Q4 2022

OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

NCE = New Chemical Entity; MOA = Mechanism of Action; PoC = Proof-of-Concept

APPENDIX

OLINVYK: Distinct From IV Morphine / Hydromorphone



Studied in >1,900 individuals

IV morphine included as active comparator

NCE with 2032+ COM patent[1]

Robust Clinical Development Program

OLINVYK studied in > 1,900 individuals



- **No dosage adjustments** for elderly / renally impaired
- No known active metabolites

4 head-to-head trials vs. IV morphine:

- IV opioid efficacy
- Rapid onset of action
- Well-characterized respiratory safety / GI tolerability
- Low rates of vomiting and rescue antiemetic use

Large safety study:

- Real-world use in complex patients and target surgeries

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

 # subjects exposed to OLINVYK in Ph1 = 318; # patients treated with OLINVYK in Ph2 and Ph3 = 1,535

OLINVYK: IV Opioid Efficacy and Rapid Onset

- Efficacy achieved in hard tissue & soft tissue models
- Rapid onset: perceptible pain relief within 2-5 minutes
- OLINVYK efficacy data in peer-reviewed journals
  The Journal of Pain Research[1] and *Pain Practice*[2]

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

1) Viscusi ER et al. J Pain Res. 2019;12:927–943. Published 2019 Mar 11. 2) Singla NK et al. Pain Pract. 2019;19:715-731. Published 2019 Jun 04.

Primary Efficacy Endpoint Achieved in Two Pivotal Studies

OLINVYK achieved IV opioid efficacy

Published in *The Journal of Pain Research*



Ph3: Hard Tissue Surgery
Mean baseline pain = 6.7



Ph3: Soft Tissue Surgery
Mean baseline pain = 7.3

Published in *Pain Practice*

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

These analyses were the prespecified primary endpoints for both studies. Section 14 of the Prescribing Information includes the SPID-24 and SPID-48 efficacy analyses that were the basis for approval. Viscusi ER et al. J Pain Res. 2019;12:927–943. Published 2019 Mar 11. Singla NK et al. Pain Pract. 2019;19:715-731. Published 2019 Jun 04. #p < 0.05 vs. placebo (unadjusted).

OLINVYK: IV Opioid Efficacy in 2 Phase 3 RCTs



Study 1 (Orthopedic – Hard Tissue)

3 PCA regimens studied (0.1, 0.35, 0.5 mg) vs. placebo; all doses P<0.01 vs. placebo

	OLINVYK			
Outcome	**0.1 mg**	**0.35 mg**	**0.5 mg**	**Placebo**
% Completed	83%	87%	84%	60%
% D/C LOE	9%	4%	5%	34%
% Rescue Meds	41%	20%	17%	77%

Study 2 (Plastic Surgery – Soft Tissue)

3 PCA regimens studied (0.1, 0.35, 0.5 mg) vs. placebo; 0.35 / 0.5 mg doses P<0.02 vs. placebo

	OLINVYK			
Outcome	**0.1 mg**	**0.35 mg**	**0.5 mg**	**Placebo**
% Completed	86%	90%	87%	74%
% D/C LOE	11%	3%	5%	22%
% Rescue Meds	31%	21%	18%	49%

Trevena

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Robust Assessment of Respiratory Safety in Phase 3 RCTs

Data included in AMCP dossier used in formulary review

- Prespecified secondary endpoint: Respiratory Safety Burden (RSB)
  - Calculated based on incidence and cumulative duration of respiratory safety events
- Full characterization of respiratory safety profile has been made available to HCPs and formulary decision makers
  - Data can be found in OLINVYK AMCP dossier and published literature



Ph3 Respiratory Safety Events[2]
(Components of the RSB calculation)

Hard Tissue

Orthopedic Surgery-Bunionectomy Study	Placebo (N=79)	Demand Dose OLINVYK 0.1 mg (N=76)	OLINVYK 0.35 mg (N=79)	OLINVYK 0.5 mg (N=79)	Morphine 1 mg (N=76)
Components of the respiratory safety burden					
≥1 respiratory safety event, n (%)	0	1 (1.3)	7 (8.9)	11 (13.9)	14 (18.4)
P-value vs morphine	0.006	0.002	0.050	0.364	–
Duration of event, mean hours (SD)	0 (N/E)	2.88 (N/E)	3.21 (2.24)	5.72 (7.44)	5.96 (4.67)
P-value vs morphine	0.102	0.140	0.260	0.186	–
Respiratory safety event measures					
Oxygen saturation <90%, n (%)	1 (1.3)	3 (3.9)	8 (10.1)	11 (13.9)	15 (19.7)
P value vs morphine	0.005	0.006	0.100	0.352	–
Respiratory rate ≤8 bpm, n (%)	0	0	1 (1.3)	1 (1.3)	4 (5.3)
P value vs morphine	0.956	0.956	0.188	0.185	–
Sedation (MRPSS ≥3), n (%)	10 (2.7)	14 (18.4)	16 (20.3)	13 (16.5)	15 (19.7)
P value vs morphine	0.242	0.838	0.926	0.610	–

Soft Tissue

Plastic Surgery-Abdominoplasty Study	Placebo (N=83)	Demand Dose OLINVYK 0.1 mg (N=77)	OLINVYK 0.35 mg (N=79)	OLINVYK 0.5 mg (N=80)	Morphine 1 mg (N=82)
Components of the respiratory safety burden					
≥1 respiratory safety event, n (%)	5 (6.0)	6 (7.8)	17 (21.5)	18 (22.5)	22 (26.8)
Odds ratio vs morphine	0.15	0.19	0.61	0.68	—
P value vs morphine	0.0003	0.0007	0.20	0.32	—
Duration of event, mean hours (SD)	9.88 (7.0)	5.51 (1.91)	6.88 (5.66)	7.07 (6.56)	6.40 (5.09)
P value vs morphine	0.52	0.29	0.78	0.76	—
Respiratory safety event measures					
Oxygen saturation <90%, n (%)	7 (8.4)	6 (7.8)	15 (19.0)	16 (20.0)	20 (24.4)
P value vs morphine	0.02	0.01	0.57	0.76	–
Respiratory rate ≤8 bpm, n (%)	1 (1.2)	0	4 (5.1)	6 (7.5)	8 (9.8)
P value vs morphine	0.054	0.95	0.38	0.84	–
Sedation (MRPSS ≥3), n (%)	15 (18.1)	8 (10.4)	19 (24.1)	18 (22.5)	21 (25.6)
P value vs morphine	0.25	0.02	0.83	0.65	–

bpm = breaths per minute; MRPSS = Moline-Roberts Pharmacologic Sedation Scale

1) Figure 2-8, Section 2.2, OLINVYK Evidence Dossier for Formulary Consideration. 2) Figures 3-4 and 3-8, Section 3.1, OLINVYK Evidence Dossier for Formulary Consideration.

Robust Assessment of GI Tolerability in Phase 3 RCTs

Data included in AMCP dossier used in formulary review

- Phase 3 pivotal trials included measurements of nausea / vomiting rates and rescue antiemetic use
- Additional exploratory post-hoc analysis was conducted using a "complete GI response" endpoint[3]
- Full characterization of GI tolerability has been made available to HCPs and formulary decision makers
  - Data can be found in OLINVYK AMCP dossier and published literature





P < 0.05 vs. morphine. 1) Figure 2-10, Section 2.2, OLINVYK Evidence Dossier for Formulary Consideration. 2) Figure 2-11, Section 2.2, OLINVYK Evidence Dossier for Formulary Consideration. 3) GI complete response defined as the proportion of patients who did not experience the AE of vomiting and did not use rescue antiemetic medication throughout their allocated treatment period in the study.

Customer Facing Organization

Partnering with Syneos Health to provide "best in class" commercial support

Syneos Health

- Allows for execution speed and flexibility in deployment
- Full range support: source, hire, train and deploy customer-facing roles
- Ability to flex as business needs evolve

40 Customer-Facing Roles

- **Sales**: Institutional Account Managers
- **Trade & Access**: Regional Account Managers
- **Medical**: Medical Science Liaisons

Launch Team: Top Talent with Hospital Experience

Role	Highlights
Medical Science Liaisons	100% with Advanced degrees 100% with Health Econ background 100% with hospital and launch experience
Regional Sales Managers	20+ Years experience Buy & Bill Hospital & ASC experience
Key Account Managers	21 years (avg) in Pharma 100% with GPO/IDN experience 100% with recent launch experience
Representatives	18 years experience 100% with recent launch experience 100% with Hospital experience Majority with therapeutic experience

Positive Feedback from Formulary Stakeholders[1]

~75% of formulary stakeholders find OLINVYK's published data clinically meaningful:[2]

Key Endpoint (vs. IV morphine)	Pharmacist (n=50)	Physician (n=50)
Respiratory Safety Events and GI Tolerability	 72%	 76%

Majority of stakeholders view IV morphine as likely to be replaced by OLINVYK:



Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

1) Qualitative Pricing research, Charles River Associates, April 2020. 2) "Are the improvements in respiratory safety events and GI tolerability clinically meaningful?" Based on OLINVYK Ph3 clinical trial data.

Omni-channel Approach for HCP Engagement

Communication across a full range of channels to maximize reach and impact



Trevena

"Now Available" Campaign

"Now Available" Website

- Order/Reimbursement/Dosing Guides
- Connect with Medical Affairs and/or Sales Rep

"Now Available" Drivers

- Programmatic Banner Ads
  - Banner ad messaging to connect HCPs through digital journey
- Journal Ads
  - Ads will run in *American Journal of Health-System Pharmacy, Pharmacy Purchasing & Products*
- Select Emails to Key Health Care Professionals
  - Emails to provide online introduction to OLINVYK

Trevena

No Accumulation Despite Repeated Dosing

Multi-Dose tQT Study



Key results

- **No accumulation through 24 hrs**
  Mean QTcI <10ms at 22 of 24 points
- **No categorical QTc outliers**
  Δ >60 ms; >500 ms absolute
- **Well tolerated, no SAEs***
  92% reached max daily dose

*The effect on QT prolongation at total cumulative daily doses >27 mg has not been studied in a thorough QT study. Total cumulative daily doses exceeding 27 mg per day may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg.

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

Trevena

3 subjects not dosed due to lack of venous access; 1 discontinuation due to a non-serious adverse event (asymptomatic non-sustained ventricular tachycardia) with confounding hypokalemia and no meaningful QT prolongation during dosing; 1 subject completed dosing but not evaluable due to equipment malfunction

Interaction Between the AT_1 Receptor and ACE2 in COVID-19

Downregulation of ACE2 by coronavirus indirectly promotes activation of the AT_1 receptor

- Coronavirus binds to and downregulates angiotensin converting enzyme 2 (ACE2)[1]
- Decrease in ACE2 elevates angiotensin II levels
  - Angiotensin II activates AT_1 receptor
  - No breakdown of angiotensin II into Ang(1-7)
    - Normally, Ang(1-7) acts as a β-arrestin-biased ligand at the AT_1 receptor[2]
    - Protective therapeutic benefits in the lungs[3]



Trevena

1) Kuba K et al., Nat Med, 2005. 2) Teixeira LB et al., Sci Rep, 2017. 3) Santos RAS et al., Physiol Rev, 2018.

TRV027 COVID-19 Study - Imperial College London

Interim review by DMSC[1] supports transition to REMAP-CAP trial

- Randomized, double-blind, placebo-controlled proof-of-concept study
- N = ~60 (30 per arm) COVID-19 patients
  - Hospitalized, non-ventilated
  - ≥18 years old
- IV infusion of placebo or TRV027 for 7 days (12 mg/hr)
- Review of interim data by DMSC found no safety concerns and supported advancement to more extensive study with clinical efficacy outcomes

ICL Winding down Study
(Transition to REMAP-CAP)

Primary ICL Endpoint:
Reduction of abnormal clotting associated with COVID-19[2]

Imperial College London

Trevena

1) DMSC = Data Monitoring & Safety Committee; 2)Primary endpoint: D-dimer levels. https://clinicaltrials.gov/ct2/show/record/NCT04419610.

Delta Receptor Agonists Have Unique Benefits

Potential utility for a variety of CNS indications

Triptans / Ditans

- Target: serotonin receptors → mediate vascular excitability (associated CV risk)[1]
- Migraine-specific treatment

CGRPs

- Target: CGRP receptors → regulate neuronal structures involved in pain signaling[2]
- Migraine-specific treatment

Delta receptor agonists

- Target: delta receptors → located in pain pathways; also distributed throughout brain regions associated with sensory information, emotional processing, and reward / impulsivity[3]
- Potential for broad therapeutic application

1) Rothrock JF & Friedman DI, American Headache Society website: https://americanheadachesociety.org/wp-content/uploads/2018/05/John_Rothrock_and_Deborah_Friedman_-_Triptans.pdf. 2) Durham PL, Headache, 2006. 3) Peppin JF & Raffa RB, Journal of Clinical Pharmacy and Therapeutics, 2015.

IMPORTANT SAFETY INFORMATION

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS

Addiction, Abuse, and Misuse

OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing OLINVYK, and monitor all patients regularly for the development of behaviors or conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK. Monitor for respiratory depression, especially during initiation of OLINVYK or following a dose increase.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Risk From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.

INDICATIONS AND USAGE

OLINVYK is a new chemical entity indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

- Have not been tolerated, or are not expected to be tolerated
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation.

CONTRAINDICATIONS

OLINVYK is contraindicated in patients with:

- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Known hypersensitivity to oliceridine (e.g., anaphylaxis)

WARNINGS AND PRECAUTIONS

- OLINVYK contains oliceridine, a Schedule II controlled substance, that exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor all patients receiving opioids.
- Serious, life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended, especially in patients with chronic pulmonary disease, or in elderly, cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy, following a dose increase, or when used with other drugs that depress respiration. Proper dosing of OLINVYK is essential, especially when converting patients from another opioid product to avoid overdose. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status.
- Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia with risk increasing in a dose-dependent fashion. In patients who present with CSA, consider decreasing the dose of opioid using best practices for opioid taper.

WARNINGS AND PRECAUTIONS

- Prolonged use of opioids during pregnancy can result in withdrawal in the neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using OLINVYK for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
- Profound sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration.
- OLINVYK was shown to have mild QTc interval prolongation in thorough QT studies where patients were dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied and may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg.
- Increased plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP) 2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely monitored for respiratory depression and sedation at frequent intervals. Concomitant use of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor can lower the expected concentration, which may decrease efficacy, and may require supplemental doses.
- Cases of adrenal insufficiency have been reported with opioid use (usually greater than one month). Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement doses of corticosteroids and wean patient from the opioid.
- OLINVYK may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients.
- There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO_2 retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO_2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
- As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO_2 retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO_2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
- As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- OLINVYK may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders for worsened seizure control.
- Do not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic effect and/or precipitate withdrawal symptoms.
- OLINVYK may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
- Although self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient to individually titrate to an acceptable level of analgesia, PCA administration has resulted in adverse outcomes and episodes of respiratory depression. Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications.

ADVERSE REACTIONS

Adverse reactions are described in greater detail in the Prescribing Information.

The most common (incidence ≥10%) adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.

Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients

--

REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19

Interim review of Imperial College London TRV027 study data supports transition to larger study

REMAP-CAP trial to study TRV027 in up to 300 patients

--

CHESTERBROOK, Pa., April 21, 2021 (GLOBE NEWSWIRE) --**Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that TRV027, the Company's novel AT_1 receptor selective agonist, has been selected for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients.

The trial is being conducted and funded as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia), a global network of clinicians, institutions, and research facilities with the objective of evaluating treatments with the potential to reduce mortality, ICU use, and morbidity in severely ill patients with COVID-19. REMAP-CAP is financially supported by an array of governments and research organizations worldwide.

"I am pleased with the addition of TRV027 to REMAP-CAP, a globally recognized research network that is leading the search for cutting-edge COVID-19 therapies," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "TRV027 holds immense potential as a treatment for the severe multi-organ damage and blood clotting caused by COVID-19, and I look forward to supporting the investigation of our novel asset in this innovative and expansive trial."

The trial, known as the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain, is designed specifically to evaluate treatments targeting the renin-angiotensin system (RAS) and determine whether modulation of the RAS is an effective strategy for preventing multiorgan failure and mortality in hospitalized COVID-19 patients. TRV027, which is based on Nobel Prize winning technology, combats disruption within the RAS by specifically binding to and rebalancing AT_1 receptor activation, blocking the damaging pathway that leads to acute lung damage and abnormal blood clotting, while activating the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.

"I am excited by the opportunity to study TRV027, a novel AT_1 receptor selective agonist, as part of REMAP-CAP's investigation of innovative treatments for COVID-19," said Anthony Gordon, M.D., Professor of Anaesthesia and Critical Care at Imperial College London and a National Institute for Health Research (NIHR) Research Professor. "REMAP-CAP's adaptive trial design allows us to gather a plethora of data on a treatment's efficacy – particularly in certain patient populations or when administered in conjunction with other types of therapies — and I look forward to seeing what information we can glean from TRV027 as we evaluate its performance in COVID-19 patients."

As previously announced, TRV027 is being investigated in a proof-of-concept study by Imperial College London. A recent review of the interim data by the study's Data Monitoring and Safety Committee (DMSC) found that there were no safety concerns with TRV027, and the DMSC supported advancing TRV027 to a larger, more extensive study with clinical efficacy outcomes. Imperial College London anticipates winding down its study in the near future and is supporting the transition of TRV027 into the REMAP-CAP COVID-19 RAS domain study. David Owen, M.D., Ph.D., the chief investigator of Imperial College London's TRV027 study, has joined the investigator team committee for the REMAP-CAP RAS domain study.

About the REMAP-CAP COVID-19 ACE2 RAS Modulation Domain

This is an international, multi-site, randomised, Phase 2-Phase 3 adaptive clinical trial in hospitalized patients with acute illness due to suspected or proven COVID-19, including patients admitted to ICU. Four active treatments are included in the study protocol, including TRV027, with 200-300 patients expected to be enrolled in each arm. TRV027 will be administered in conjunction with an ACE inhibitor. The primary outcome is a composite of in-hospital mortality and provision of organ failure support while admitted to an ICU in the 21 days following randomization. The trial is also evaluating clinical outcomes including ICU and hospital length of stay, ventilator-free days, and organ failure-free days.

About REMAP-CAP

REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) is a platform trial designed by clinicians who cared for patients and conducted research during the 2009 H1N1 pandemic. Planning began in 2011. REMAP-CAP is supported by multiple government grants.

REMAP-CAP builds on the combined input of the world's leading ICU trial networks and experts in infectious disease, immunology, critical care, emergency medicine, Bayesian statistics, and clinical trial execution. These existing networks have enrolled tens of thousands of patients into trials. They have extensive experience designing, conducting, and reporting clinical trials that enroll patients who are severely ill.

The goal of REMAP-CAP is to generate evidence that can be applied during the pandemic to reduce mortality, reduce ICU use, and reduce morbidity in severely ill patients with COVID-19 infection. For the past several years, REMAP-CAP has been recruiting patients with severe CAP in the inter-pandemic period. REMAP-CAP is currently recruiting in more than 300 sites across 21 countries. REMAP-CAP was designed to adapt to an acute pandemic need: that time came slightly over a year ago. Changes necessary for the pandemic have been approved or submitted for approval and many patients with COVID-19 have been and are being enrolled. More information can be found at https://www.remapcap.org/.

About TRV027

TRV027 is a novel AT1 receptor selective agonist that is currently being investigated by multiple institutions as a potential treatment for acute lung injury contributing to ARDS and abnormal blood clotting in COVID-19 patients. It has previously been studied in 691 individuals, has a well-characterized pharmacokinetic profile, and has demonstrated efficacy, potency, and selectivity at the AT1 receptor in nonclinical studies. In previous clinical trials, there was a low dropout rate associated with TRV027, and no significant

safety issues were reported. In April 2021, the Company filed a non-provisional patent application and PCT application with the United States Patent and Trademark Office covering the use of TRV027 to treat ARDS and the prevention or treatment of abnormal clotting in COVID-19 patients.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company's novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with FDA, the timing of FDA's decision on the oliceridine NDA; available funding ; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

For more information, please contact:

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

PR & Media Contact:
Sasha Bennett
Director
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409
